Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by D.F. Courmier
Php240 - Health Technology Assessments of Bevacizumab Biosimilars: Could a Demonstration of Cost-Effectiveness Change the Recommendation for Reimbursement Versus the Originator?
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Related publications
Cost-Effectiveness of Early Treatment With Originator Biologics or Their Biosimilars After Methotrexate Failure in Patients With Established Rheumatoid Arthritis
Advances in Therapy
Medicine
Pharmacology
Php232 - A Comparison of Cost-Effectiveness Assessments Between Nice and SMC Technology Appraisals
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Php291 - Shaping the Future of European Health Technology Assessments: Experiences of Three Pharmaceutical Joint Rapid Relative Effectiveness Assessments
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Population Health and Cost-Effectiveness Implications of a “Treat All” Recommendation for HCV: A Review of the Model-Based Evidence
MDM Policy and Practice
Health Policy
Public Health
Occupational Health
Environmental
Bevacizumab for Metastatic Colorectal Cancer: A Global Cost‐Effectiveness Analysis
Oncologist
Cancer Research
Medicine
Oncology
Clinical Effectiveness and Cost-Effectiveness of Sugammadex for Reversal of Neuromuscular Block: A Rapid Health Technology Assessment
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
PHP38 Point-Of-Care Diagnostic Test Reimbursement and Market Access: Lessons From a Survey of Global Health Technology Assessments
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
The “100 Lobsters” Project: A Cooperative Demonstration Project for Health Assessments of Lobsters From Rhode Island
Journal of Shellfish Research
Aquatic Science
An Examination of the Regulatory and Reimbursement Processes for Biobetters and Comparison With Biosimilars
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
